BRPI0819690B8 - uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas - Google Patents

uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas

Info

Publication number
BRPI0819690B8
BRPI0819690B8 BRPI0819690A BRPI0819690A BRPI0819690B8 BR PI0819690 B8 BRPI0819690 B8 BR PI0819690B8 BR PI0819690 A BRPI0819690 A BR PI0819690A BR PI0819690 A BRPI0819690 A BR PI0819690A BR PI0819690 B8 BRPI0819690 B8 BR PI0819690B8
Authority
BR
Brazil
Prior art keywords
cysteamine
cystamine
composition
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BRPI0819690A
Other languages
English (en)
Inventor
Schneider Jerry
Dohil Ranjan
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40679016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0819690(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Publication of BRPI0819690A2 publication Critical patent/BRPI0819690A2/pt
Publication of BRPI0819690B1 publication Critical patent/BRPI0819690B1/pt
Publication of BRPI0819690B8 publication Critical patent/BRPI0819690B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

uso de um produto de cisteamina, e, de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas. a revelação, no geral, diz respeito ao tratamento de desordens de gordura no fígado compreendendo administrar composições compreendendo produtos de cisteamina. a revelação fornece administração de composições de cisteamina entericamente revestidas para tratar desordens de gordura no fígado, tais como doença do fígado gorduroso não alcoólica (nafld) e esteatohepatite não alcoólica (nash).
BRPI0819690A 2007-11-30 2008-11-28 uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas BRPI0819690B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99151707P 2007-11-30 2007-11-30
US60/991517 2007-11-30
US8539708P 2008-07-31 2008-07-31
US61/085397 2008-07-31
PCT/US2008/085064 WO2009070781A1 (en) 2007-11-30 2008-11-28 Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products

Publications (3)

Publication Number Publication Date
BRPI0819690A2 BRPI0819690A2 (pt) 2014-10-07
BRPI0819690B1 BRPI0819690B1 (pt) 2019-07-30
BRPI0819690B8 true BRPI0819690B8 (pt) 2021-05-25

Family

ID=40679016

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0819690A BRPI0819690B8 (pt) 2007-11-30 2008-11-28 uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas

Country Status (26)

Country Link
US (5) US7994226B2 (pt)
EP (2) EP2214480B1 (pt)
JP (3) JP5583022B2 (pt)
KR (1) KR20100091219A (pt)
CN (2) CN104825430B (pt)
AR (1) AR069500A1 (pt)
AU (1) AU2008329628B2 (pt)
BR (1) BRPI0819690B8 (pt)
CA (1) CA2706768C (pt)
CL (1) CL2008003582A1 (pt)
CY (1) CY1114126T1 (pt)
DK (1) DK2214480T3 (pt)
ES (1) ES2417179T3 (pt)
HK (1) HK1141945A1 (pt)
HR (1) HRP20130590T1 (pt)
IL (2) IL205909B (pt)
MX (2) MX360827B (pt)
MY (1) MY156316A (pt)
NZ (1) NZ585732A (pt)
PL (1) PL2214480T3 (pt)
PT (1) PT2214480E (pt)
RU (1) RU2498795C2 (pt)
SG (1) SG10201403200RA (pt)
TW (2) TWI478710B (pt)
WO (1) WO2009070781A1 (pt)
ZA (1) ZA201003670B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0707277B1 (pt) 2006-01-27 2021-07-13 The Regents Of The University Of California Composição, uso da mesma,e , formulação famacêutica
JP5583022B2 (ja) 2007-11-30 2014-09-03 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア システアミン生成物を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の治療方法
CA2798735A1 (en) * 2010-05-19 2011-11-24 Haruki Shibata Prophylactic and/or therapeutic agent for non-alcoholic steatohepatitis
SG185754A1 (en) * 2010-06-08 2012-12-28 Mahesh Kandula Cysteamine derivatives and their use in the treatment of nash
US20140187594A1 (en) * 2010-07-28 2014-07-03 Orchid Chemicals And Pharmaceuticals Ltd Diphenyl ether compounds for the treatment of liver, lung disorders, diabetic complications and cardiovascular diseases
WO2014045293A1 (en) * 2012-09-24 2014-03-27 Krisani Bioscience (P) Ltd. Fatty acid amides with a cysteamine or an acetylated cysteamine group and uses thereof
ES2869884T3 (es) 2011-09-16 2021-10-26 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y la enfermedad de hígado graso no alcohólico
WO2013062544A1 (en) 2011-10-26 2013-05-02 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
RU2638807C2 (ru) * 2011-11-22 2017-12-15 Те Риджентс Оф Те Юниверсити Оф Калифорния Способы и композиции для лечения воспаления и ишемического поражения
AU2013237881B2 (en) * 2012-03-29 2017-10-12 Akashi Therapeutics, Inc. Dosage forms of halofuginone and methods of use
MX2014014979A (es) 2012-06-06 2015-06-17 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de las enfermedades asociadas con la sintasa de oxido nitrico inducible elevada.
US20140314841A1 (en) 2013-04-19 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
BR112016024020A8 (pt) * 2014-04-18 2021-07-20 Lg Chemical Ltd composição farmacêutica
RU2746091C2 (ru) * 2015-03-03 2021-04-06 Кодзин Лайф Сайенсиз Ко., Лтд. Композиция для улучшения или профилактики неалкогольной жировой дистрофии печени
WO2017004485A1 (en) 2015-07-02 2017-01-05 Raptor Pharmaceuticals Inc. Ado-resistant cysteamine analogs and uses thereof
RU2595815C1 (ru) * 2015-07-13 2016-08-27 федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Западный государственный медицинский университет им. И.И. Мечникова" Министерства здравоохранения Российской Федерации Способ лечения больных неалкогольным стеатогепатитом на фоне метаболического синдрома
US10537528B2 (en) 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
IL261756B2 (en) 2016-03-17 2023-11-01 Thiogenesis Therapeutics Inc Preparations for the controlled release of cysteamine and systemic treatment of disorders sensitive to cysteamine
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
JP7270979B2 (ja) * 2017-06-08 2023-05-11 エヌ－ジーン リサーチ ラボラトリーズ，アイエヌシー． Ｎａｓｈ治療方法及びｎａｓｈ誘発性ｈｃｃ予防方法
WO2019046659A1 (en) * 2017-08-30 2019-03-07 First Fruits Business Ministry, Llc COMPOSITION AND METHOD FOR INCREASING SERIAL ADIPONECTIN AND REDUCING THE LIPID RESERVES OF THE ORGANISM
JP7208982B2 (ja) 2017-09-20 2023-01-19 チオジェネシス セラピューティクス， インコーポレイテッド システアミン感受性障害の治療方法
KR102177304B1 (ko) * 2018-07-23 2020-11-10 제이투에이치바이오텍 (주) 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
CN111544426A (zh) * 2019-02-12 2020-08-18 复旦大学 炔丙基半胱氨酸及其在制备新靶点药物中的用途
AU2020316017A1 (en) * 2019-07-19 2022-02-17 Filtricine, Inc. Compositions, methods, kits and systems for cancer treatment and metabolic intervention therapy and other uses
CN111505099B (zh) * 2020-04-21 2023-07-04 上海市普陀区中心医院 Nash的诊断标志物及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110441A (en) 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
US4959306A (en) * 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5639743A (en) * 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
JPH11302178A (ja) * 1998-02-17 1999-11-02 Otsuka Pharmaceut Factory Inc 脂肪肝予防及び治療剤
US20050059576A1 (en) * 1998-04-30 2005-03-17 Adamson J. Gordon Targeted delivery of antiviral compounds through hemoglobin bioconjugates
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2001058708A1 (en) * 2000-02-14 2001-08-16 Len Booysen Stabilizer unit
CN1144585C (zh) * 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
US7449451B2 (en) * 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
CN1596111A (zh) * 2001-11-29 2005-03-16 桑得医药品公司 减轻化疗引起的不良效果的组合物及方法
DK1471902T3 (da) * 2002-01-04 2014-09-08 Sound Pharmaceuticals Inc Sammensætninger til brug i fremgangsmåder til behandling af høretab
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
JP2004026716A (ja) 2002-06-25 2004-01-29 Ajinomoto Co Inc ＴＮＦα産生の抑制剤
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
CN100391448C (zh) 2003-11-19 2008-06-04 奥加生物药业(I.P.1)有限公司 提高乙醇代谢和减轻宿醉效应的物质和方法
ATE515261T1 (de) 2003-12-19 2011-07-15 Omega Bio Pharma Ip3 Ltd Zusammensetzungen zur behandlung von diabetes
WO2005092914A1 (en) * 2004-03-22 2005-10-06 Blue Mountain Technology Development Lab Process for promoting proper folding of human serum albumin using a human serum albumin ligand
CA2565250C (en) 2004-05-03 2013-11-12 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
JP2008526789A (ja) 2005-01-05 2008-07-24 アーメッド コトブ アブダラ，マグド タウリンの合成、生成及び医薬としての利用
AU2006236150A1 (en) * 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
AU2006331770A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
US20070172514A1 (en) * 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
BRPI0707277B1 (pt) * 2006-01-27 2021-07-13 The Regents Of The University Of California Composição, uso da mesma,e , formulação famacêutica
WO2007121545A1 (en) * 2006-04-20 2007-11-01 Universidade Estadual De Campinas-Unicamp S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
AU2007248483A1 (en) 2006-05-03 2007-11-15 Geisinger Clinic Methods for diagnosing and predicting non-alcoholic steatohepatitis (NASH)
US20100028319A1 (en) 2007-02-02 2010-02-04 Kaneka Corporation Composition for prevention or treatment of diabetes
JP5583022B2 (ja) * 2007-11-30 2014-09-03 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア システアミン生成物を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の治療方法

Also Published As

Publication number Publication date
JP5583022B2 (ja) 2014-09-03
US8263662B2 (en) 2012-09-11
TWI478710B (zh) 2015-04-01
MX360827B (es) 2018-11-16
BRPI0819690A2 (pt) 2014-10-07
US20120015005A1 (en) 2012-01-19
TW201513855A (zh) 2015-04-16
NZ585732A (en) 2012-02-24
RU2498795C2 (ru) 2013-11-20
CN101932238A (zh) 2010-12-29
EP2214480A4 (en) 2010-09-29
MX2010005921A (es) 2010-06-11
WO2009070781A1 (en) 2009-06-04
JP2011505375A (ja) 2011-02-24
ZA201003670B (en) 2011-08-31
CY1114126T1 (el) 2016-07-27
IL205909A0 (en) 2010-11-30
US20100303870A1 (en) 2010-12-02
EP2214480A1 (en) 2010-08-11
US20130183351A1 (en) 2013-07-18
TWI535435B (zh) 2016-06-01
RU2010126631A (ru) 2012-01-10
SG10201403200RA (en) 2014-10-30
MY156316A (en) 2016-02-11
IL254586A0 (en) 2017-11-30
CA2706768C (en) 2016-06-28
JP6121951B2 (ja) 2017-04-26
PL2214480T3 (pl) 2013-11-29
PT2214480E (pt) 2013-07-23
US7994226B2 (en) 2011-08-09
US9511038B2 (en) 2016-12-06
CL2008003582A1 (es) 2009-04-03
AU2008329628B2 (en) 2014-06-26
HK1141945A1 (en) 2010-11-26
JP2014237670A (ja) 2014-12-18
ES2417179T3 (es) 2013-08-06
US20160143865A1 (en) 2016-05-26
TW200927093A (en) 2009-07-01
EP2636404A2 (en) 2013-09-11
CA2706768A1 (en) 2009-06-04
US20170304233A1 (en) 2017-10-26
CN104825430A (zh) 2015-08-12
CN104825430B (zh) 2018-05-04
US10307386B2 (en) 2019-06-04
AU2008329628A1 (en) 2009-06-04
DK2214480T3 (da) 2013-07-08
EP2214480B1 (en) 2013-03-27
HRP20130590T1 (en) 2013-08-31
AR069500A1 (es) 2010-01-27
KR20100091219A (ko) 2010-08-18
BRPI0819690B1 (pt) 2019-07-30
IL205909B (en) 2018-05-31
EP2636404B1 (en) 2019-03-20
US9149448B2 (en) 2015-10-06
JP2017165735A (ja) 2017-09-21
CN101932238B (zh) 2015-04-08
EP2636404A3 (en) 2013-10-16

Similar Documents

Publication Publication Date Title
BRPI0819690B8 (pt) uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BR112018008805A2 (pt) proteínas de função dupla e composição farmacêutica que compreende a mesma
BR112015020600A2 (pt) composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
BR112014031394A2 (pt) composições e métodos para absorção transmucosa
BR112013016021A2 (pt) métodos e composições adequadas para gerenciar glicemia em animais
FR2949044B1 (fr) Composition comprenant une fraction d&#39;insaponifiable
BR112014009097A2 (pt) composição para uso na promoção de crescimento de osso saudável e/ou na prevenção e/ou tratamento das doenças dos ossos
CY1115725T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων
BR112012006010A2 (pt) composto de glicina
SG10201906400SA (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
BR102018016746A8 (pt) Composição farmacêutica para prevenção de obesidade induzida por dieta
MX2017006639A (es) Metodos y composiciones para preservar la masa corporal magra y promover la perdida de grasa durante la perdida de peso.
EA201692106A1 (ru) Пищевые продукты, системы, способы и наборы для замены электролитов
BRPI0712561B8 (pt) Uso de 3-oxo-3,4-diidro-2-pirazinacarboxamida
EP3852760A4 (en) MATTER ON THE COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF THE ANALOGUES DERIVED FROM FL118 PLATFORM POSITIONS 7 AND 9 FOR THE TREATMENT OF HUMAN DISEASES
MX2022004382A (es) Metodos para promover la produccion de scfa por microbiota intestinal.
BR112013003064A2 (pt) agente profilático ou terapêutico para a esteato-hepatite não alcoólica
WO2018093237A3 (ko) 포름산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물
RU2013133998A (ru) Способы и композиции для предотвращения и лечения остеоартрита
BR112014001503A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para o tratamento de doenças de pele
MX2021003030A (es) Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion.
WO2018078599A3 (en) Composition for the preventive or curative treatment of liver disorders
BR112014001538A2 (pt) composições farmacêuticas compreendendo 4-bromo-n-(imidazolidin-2-ilideno)-1h-benzimidazol-5-amina para tratamento de doenças retinais

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/11/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2646 DE 21-09-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.